HYDROXOCOBALAMIN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Hydroxocobalamin, and when can generic versions of Hydroxocobalamin launch?
Hydroxocobalamin is a drug marketed by Abraxis Pharm, Actavis, and Watson Labs. and is included in three NDAs.
The generic ingredient in HYDROXOCOBALAMIN is hydroxocobalamin. There are four drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the hydroxocobalamin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Hydroxocobalamin
A generic version of HYDROXOCOBALAMIN was approved as hydroxocobalamin by ACTAVIS on December 31st, 1969.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for HYDROXOCOBALAMIN?
- What are the global sales for HYDROXOCOBALAMIN?
- What is Average Wholesale Price for HYDROXOCOBALAMIN?
Summary for HYDROXOCOBALAMIN
| US Patents: | 0 |
| Applicants: | 3 |
| NDAs: | 3 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| Clinical Trials: | 11 |
| Patent Applications: | 246 |
| Drug Prices: | Drug price information for HYDROXOCOBALAMIN |
| DailyMed Link: | HYDROXOCOBALAMIN at DailyMed |
Recent Clinical Trials for HYDROXOCOBALAMIN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Mayo Clinic | Phase 4 |
| General Oncology, Inc. | Phase 1 |
| Joshua Korzenik | Phase 2 |
Pharmacology for HYDROXOCOBALAMIN
| Drug Class | Antidote |
Medical Subject Heading (MeSH) Categories for HYDROXOCOBALAMIN
Anatomical Therapeutic Chemical (ATC) Classes for HYDROXOCOBALAMIN
US Patents and Regulatory Information for HYDROXOCOBALAMIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abraxis Pharm | HYDROXOCOBALAMIN | hydroxocobalamin | INJECTABLE;INJECTION | 084921-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Actavis | HYDROXOCOBALAMIN | hydroxocobalamin | INJECTABLE;INJECTION | 085998-001 | Approved Prior to Jan 1, 1982 | RX | No | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Watson Labs | HYDROXOCOBALAMIN | hydroxocobalamin | INJECTABLE;INJECTION | 085528-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for HYDROXOCOBALAMIN
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| SERB SA | Cyanokit | hydroxocobalamin | EMEA/H/C/000806 Treatment of known or suspected cyanide poisoning.Cyanokit is to be administered together with appropriate decontamination and supportive measures. |
Authorised | no | no | no | 2007-11-23 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
